John L Krstenansky

List of Publications by Year
in descending order

71 papers	1,983 citations	201575 27 h-index	254106 43 g-index
71 all docs	71 docs citations	71 times ranked	1123 citing authors

#	Article	IF	Citations
1	ACE2â€‰:â€‰S1 RBD Interaction-Targeted Peptides and Small Molecules as Potential COVID-19 Therapeutics. Advances in Pharmacological and Pharmaceutical Sciences, 2021, 2021, 1-10.	0.7	5
2	Identification of potential binding pocket on viral oncoprotein HPV16 E6: a promising anti-cancer target for small molecule drug discovery. BMC Molecular and Cell Biology, 2019, 20, 30.	1.0	21
3	Synthesis and pharmacological characterization of ethylenediamine synthetic opioids in human Î¼â€opiate receptor 1 (OPRM1) expressing cells. Pharmacology Research and Perspectives, 2019, 7, e00511.	1.1	14
4	Mesembrine alkaloids: Review of their occurrence, chemistry, and pharmacology. Journal of Ethnopharmacology, 2017, 195, 10-19.	2.0	37
5	Analysis of the Smoke of Cigarettes Containing Salvia divinorum. Journal of Analytical Toxicology, 2014, 38, 451-455.	1.7	0
6	Small molecule inhibitors of the HPV16-E6 interaction with caspase 8. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2125-2129.	1.0	36
7	Adrenochrome and related oxidative metabolites of catecholamines: Effects on dopamine neurons and receptor binding profiles. Schizophrenia Research, 2011, 133, 264-265.	1.1	0
8	Probing Proteinase Active Sites Using Oriented Peptide Mixture Libraries - ADAM-10. Letters in Drug Design and Discovery, 2004, 1, 6-13.	0.4	2
9	Replacements at positions 17, 18, and 21 of glucagon leads to formation of a new salt bridge and to an increase in binding affinities. , 2002, , 619-620.		0
10	Biocatalytic combinatorial synthesis. Bioorganic and Medicinal Chemistry, 1999, 7, 2157-2162.	1.4	38
11	Identification of Residues in the Monocyte Chemotactic Protein-1 That Contact the MCP-1 Receptor, CCR2â€. Biochemistry, 1999, 38, 13013-13025.	1.2	141
12	Structureâ^'Function Studies on Positions 17, 18, and 21 Replacement Analogues of Glucagon:Â The Importance of Charged Residues and Salt Bridges in Glucagon Biological Activityâ€. Journal of Medicinal Chemistry, 1998, 41, 2693-2700.	2.9	22
13	Nonpeptide bradykinin antagonist analogs based on a model of a Sterling-Winthrop nonpeptide bradykinin antagonist overlapped with cyclic hexapeptide bradykinin antagonist peptides. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 1921-1926.	1.0	6
14	Combinatorial synthesis of small-molecule libraries using 3-amino-5-hydroxybenzoic acid. Molecular Diversity, 1996, 1, 113-120.	2.1	20
15	RS-66271, a C-terminally substituted analog of human parathyroid hormone-related protein (1â€“34), increases trabecular and cortical bone in ovariectomized, osteopenic rats. Journal of Bone and Mineral Research, 1996, 11, 1943-1951.	3.1	40
16	Cyclic hexapeptide antagonists of the bradykinin B2 receptor: Receptor binding and solution backbone conformation. International Journal of Peptide Research and Therapeutics, 1995, 1, 229-234.	0.1	5
17	Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34).. Endocrinology, 1995, 136, 3624-3631.	1.4	109
18	Solid Phase Synthesis of Aryl and Benzylpiperazines and their Application in Combinatorial Chemistry. Tetrahedron Letters, 1995, 36, 4923-4926.	0.7	48

#	Article	IF	Citations
19	Solid phase synthesis of aryl and benzylpiperazines and their application in combinatorial chemistry. Tetrahedron Letters, 1995, 36, 4923-4926.	0.7	28
20	Neuropeptide Y and truncated neuropeptide Y analogs evoke histamine release from rat peritoneal mast cells. A direct effect on G proteins?. European Journal of Pharmacology, 1994, 258, 163-166.	1.7	22
21	Binding of Fluorescent and Spin-Labeled C-Terminal Hirudin Analogs to Thrombin. Journal of Medicinal Chemistry, 1994, 37, 3855-3858.	2.9	2
22	Design and synthesis of a bicyclic non-peptide Î²-bend mimetic of enkephalin. Tetrahedron, 1993, 49, 3489-3500.	1.0	10
23	Activation of neuropeptide Y1 and neuropeptide Y2 receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes. European Journal of Pharmacology, 1993, 232, 271-278.	1.7	41
24	An Amphipathic Î±-Helical Decapeptide in Phosphatidylcholine Is an Effective Synthetic Lung Surfactant. The American Review of Respiratory Disease, 1993, 147, 462-465.	2.9	26
25	Specific inhibition of binding of antistasin and [A103,106,108] antistasin 93-119 to sulfatide (Gal(3-SO4)Î²1-1Cer) by glycosaminoglycans. FEBS Letters, 1992, 296, 145-147.	1.3	3
26	Evidence for a lysine-specific fragmentation in fast-atom bombardment mass spectra of peptides. Rapid Communications in Mass Spectrometry, 1992, 6, 257-264.	0.7	5
27	The synthesis of synâ€•and antiâ€2(S)â€phthalimidoâ€•methylâ€2,3,4,4a,7,7aâ€hexahydroâ€6â€oxoâ€5Hâ€pyranoâ€[2,3â€b]pyrroles as rigid Î²â€bend peptideâ€•mimetics. Journal of Heterocyclic Chemistry, 1992, 29, 707-711.		1
28	The fibrinogen anion-binding exosite of thrombin is necessary for induction of rises in intracellular calcium and prostacyclin production in endothelial cells. Journal of Cellular Physiology, 1992, 151, 190-196.	2.0	13
29	NPY and PYY analogs as antisecretory agents. , 1992, , 136-137.		0
30	Demonstration that [A103,106,108] antistasin 93â€“119 inhibits the specific binding of antistasin to sulfatide [Gal(3-SO4)Î²1-1Cer]. Biochemical and Biophysical Research Communications, 1991, 181, 246-251.	1.0	2
31	Minimal peptide length for interaction of amphipathic .alpha.-helical peptides with phosphatidylcholine liposomes. Biochemistry, 1991, 30, 31-37.	1.2	97
32	Positional effects of sulfation in hirudin and hirudin PA related anticoagulant peptides. Journal of Medicinal Chemistry, 1991, 34, 1184-1187.	2.9	9
33	Minimal peptide length for interaction of amphipathic .alpha.-helical peptides with phosphatidylcholine liposomes [Erratum to document cited in CA114(3):19749v]. Biochemistry, 1991, 30, 11004-11004.	1.2	0
34	Examination of the peptide sequence requirements for lipid-binding. Alternative pathways for promoting the interaction of amphipathic Î±-helical peptides with phosphatidylcholine. Lipids and Lipid Metabolism, 1991, 1086, 106-114.	2.6	10
35	The effects of selective amino acid substitution upon neuropeptide Y antisecretory potency in rat jejunum mucosa. Peptides, 1991, 12, 323-327.	1.2	28
36	Structure - function relationships of the C-terminal functional domain of hirudin and its variants. Blood Coagulation and Fibrinolysis, 1991, 2, 91-96.	0.5	2

#	Article	IF	Citations
37	Effect of the Hirudin Carboxy-Terminal Peptide 54-65 on the Interaction of Thrombin with Platelets. Thrombosis and Haemostasis, 1991, 66, 300-305.	1.8	27
38	Examination of the role of the amphipathic .alpha.-helix in the interaction of neuropeptide Y and active cyclic analogs with cell membrane receptors and dimyristoylphosphatidylcholine. Biochemistry, 1990, 29, 2016-2022.	1.2	61
39	Centrally truncated neuropeptide Y analog acts as an agonist for Y1 receptors on SK-N-MC cells. Neuroscience Letters, 1990, 119, 187-190.	1.0	9
40	Signal Epitopes in the Three-Dimensional Structure of Neuropeptide Y.. Annals of the New York Academy of Sciences, 1990, 611, 35-47.	1.8	102
41	C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor. Neuropeptides, 1990, 17, 117-120.	0.9	30
42	The C-terminal binding domain of hirullin P18. FEBS Letters, 1990, 269, 425-429.	1.3	10
43	Lipid and membrane interactions of neuropeptide Y. Biochimica Et Biophysica Acta - Biomembranes, 1990, 1024, 1-4.	1.4	16
44	Characterization of a Monoclonal Antibody Specific to the Amino Terminus of the Î±-Chain of Human Fibrin. Thrombosis and Haemostasis, 1990, 63, 445-448.	1.8	11
45	Development of MDL 28,050, a Small Stable Antithrombin Agent Based on a Functional Domain of the Leech Protein, Hirudin. Thrombosis and Haemostasis, 1990, 63, 208-214.	1.8	53
46	C-Terminal peptide alcohol, acid and amide analogs of desulfato hirudin54â€“65 as antithrombin agents. Thrombosis Research, 1989, 54, 319-325.	0.8	7
47	Preparation of antibodies to a synthetic C terminus of hirudin and identification of an antigenic site. Journal of Immunological Methods, 1989, 120, 45-50.	0.6	6
48	Effect of micelle diameter on tryptophan dynamics in an amphipathic helical peptide in phosphatidylcholine. Biochemistry, 1989, 28, 8403-8410.	1.2	13
49	Short model peptides having a high Î±-helical tendency: Design and solution properties. FEBS Letters, 1989, 242, 409-413.	1.3	31
50	Human hepatoma (HepG2) cells secrete a single 65 K Dalton triglyceride lipase immunologically identical to postheparin plasma hepatic lipase. Life Sciences, 1989, 45, 615-622.	2.0	10
51	Centrally truncated and stabilized porcine neuropeptide Y analogs: design, synthesis, and mouse brain receptor binding.. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 4377-4381.	3.3	81
52	Design, synthesis and antithrombin activity for conformationally restricted analogs of peptide anticoagulants based on the C-terminal region of the leech peptide, hirudin. BBA - Proteins and Proteomics, 1988, 957, 53-59.	2.1	14
53	N-Terminal requirements of small peptide anticoagulants based on hirudin 54-65. Journal of Medicinal Chemistry, 1988, 31, 1009-1011.	2.9	19
54	Inhibition of lymphocyte proliferation by synthetic peptides homologous to human plasma apolipoproteins B and E. Biochemical and Biophysical Research Communications, 1988, 154, 741-745.	1.0	29

#	Article	IF	Citations
55	Comparison of hirudin and hirudin PA C-terminal fragments and related analogs as antithrombin agents. Thrombosis Research, 1988, 52, 137-141.	0.8	15
56	Interaction of hirudin with thrombin: identification of a minimal binding domain of hirudin that inhibits clotting activity. Biochemistry, 1988, 27, 8170-8173.	1.2	134
57	A tachykinin peptide receptor joins an elite club. Trends in Pharmacological Sciences, 1988, 9, 3-5.	4.0	19
58	Immunological identification of a high molecular weight protein as a candidate for the product of the Duchenne muscular dystrophy gene.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 4491-4495.	3.3	13
59	Fluorescence Quenching And Multiple-Frequency Phase Fluorometry In Peptide-Lipid Micelles. , 1988, 0909, 442.		0
60	Importance of the Câ€terminal Î±â€helical structure for glucagon's biological activity. International Journal of Peptide and Protein Research, 1988, 32, 468-475.	0.1	14
61	Interaction of the dogfish cyclic tachykinin scyliorhinin II with tachykinin NK-1 and NK-2 binding sites. , 1988, , 617-618.		0
62	Characterization of the interaction of thrombin with the C-terminal region of the leech anticoagulant peptide hirudin. , 1988, , 447-448.		0
63	The synthesis, physical characterization and receptor binding affinity of neuropeptide Y (NPY). Neuropeptides, 1987, 10, 77-85.	0.9	52
64	The dogfish peptides scyliorhinin I and scyliorhinin II bind with differential selectivity to mammalian tachykinin receptors. European Journal of Pharmacology, 1987, 144, 109-111.	1.7	32
65	Antithrombin properties of C-terminus of hirudin using synthetic unsulfatedNÎ±-acetyl-hirudin45-65. FEBS Letters, 1987, 211, 10-16.	1.3	103
66	Rapid purification and revised amino-terminal sequence of hirudin: A specific thrombin inhibitor of the bloodsucking leech. Analytical Biochemistry, 1987, 161, 514-518.	1.1	28
67	Anticoagulant peptides. Nature of the interaction of the C-terminal region of hirudin with a noncatalytic binding site on thrombin. Journal of Medicinal Chemistry, 1987, 30, 1688-1691.	2.9	57
68	Conformational considerations in the design of a glucagon analog with increased receptor binding and adenylate cyclase potencies. Journal of the American Chemical Society, 1986, 108, 1696-1698.	6.6	37
69	Importance of the 10-13 region of glucagon for its receptor interactions and activation of adenylate cyclase. Biochemistry, 1986, 25, 3833-3839.	1.2	42
70	Chapter 30. Recent Progress in the Rational Design of Peptide Hormones and Neurotransmitters. Annual Reports in Medicinal Chemistry, 1984, , 303-312.	0.5	16
71	A new approach to conformationally restricted peptide analogs: Rigid Î²-bends. 1. Enkephalin as an example. Biochemical and Biophysical Research Communications, 1982, 109, 1368-1374.	1.0	39